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Abstract
A mathematical model for the quantitative analysis of cancer immune interaction,
considering the role of antibodies has been proposed in this paper. The model is
based on the clinical evidence, which states that antibodies can directly kill can-
cerous cells [1]. The existence of transcritical and saddle-node bifurcation, which
has been proved using Sotomayor theorem, provides strong biological implications.
Through numerical simulations, it has been illustrated that under certain therapy
(like monoclonal antibody therapy), which is capable of altering the parameters of
the system, cancer-free state can be obtained.
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1 Introduction
Cancer is a leading cause of death worldwide. It is predicted to remain so for
years to come unfortunately. It is a disease which is caused by the abnormal
function of our own cells. Cancer is not a single disease; it comprises more
than 200 diseases [2,3] which share common characteristics, that is, they are
abnormal cells where the normal processes which regulate normal cell prolif-
eration, differentiation and death (cell apoptosis) are interrupted. The causes
of cancer are changes that cause normal cells to acquire abnormal functions.
These causes may be the result of inherited mutation or environmental factors
such as tobacco products, ultraviolet radiation, X-rays, chemicals, etc [3]. A
normal cell can be transformed into a cancerous cell when certain genes are ac-
tivated or inactivated because of these mutation and environmental factors. In
cancerous cells the normal control system that prevent abnormal cell growth
and differentiation and the invasion of other tissues and organs are disabled.
The immune system, which is a complex network of cells, cytokines, lym-
phoid tissues and organs that work together, helps the host in fighting against
pathogenic micro organisms and cancerous cells. When cancerous cells prolif-
erate to a detectable threshold number in a given physiological space of the
human anatomy, the body’s own immune system is triggered into a search
and destroy mode [4]. The various components of the immune system interact
with each other and the cancerous cells to prevent our body from cancer and
they also help in preventing the occurrence, development and recurrence of
cancer. But sometimes cancerous cells are able to overcome the limitations
imposed by the immune system and are able to successfully proliferate and
propagate in the human body. The defense mechanisms of the human body
against external invaders and other pathogens has two major components;
innate (or natural) and adaptive (or acquired) immune systems. The innate
immune system comprises cells and mechanisms that defend the human body
from infection by other organisms and pathogens in a non specific manner.
Innate immune responses are stimulated by structures that are common to
groups of related pathogenic agents and may not distinguish fine differences
among foreign substances and it does not confer long lasting or protective
immunity in our body.
The major components of innate immune system are natural killer (NK) cells,
dendritic and mast cells, macrophages and natural antibody producing cells.
This immune system which is naturally present in our body even in the absence
of external invaders or cancerous cells, provide immediate defense against in-
fection. The biological mechanisms of innate immune system are integrated
with that of adaptive immune system by stimulating and influencing the na-
ture of the adaptive immune responses. The acquired immune responses are
highly specific for a particular pathogen. These immune responses are charac-
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terized by an exquisite specificity for distinct external invaders and pathogens
and the ability to remember and respond more vigorously to repeated ex-
posures to the same pathogens. Adaptive immune system responses against
external invaders and pathogens are mediated by a special group of immune
cells called lymphocytes through either the anti-body (humoral) mediated or
cell-mediated immune responses [2,4]. The most important cells in acquired
immune system are lymphocytes, which are small round cells that are found
in blood, lymph and connective tissue. The two major components of lympho-
cytes are the B-cells and the T-cells [5]. Both B-cells and T-cells are derived
from the stem cells residing in the bone marrow. Cells which are destined
to become T-lymphocyte undergo further differentiation in the thymus while
the precursors of B-lymphocyte differentiate in other lymphoid organs. The
B-lymphocytes are responsible for antibody mediated immune response and
the T-lymphocytes are responsible for cell-mediated immune responses.
The theoretical study of cancer-immune dynamics, which has a long history,
has been done by many authors [6,7,8,9,10,11,12,13,14,15,16,17,18] . We first
look through some of the existing mathematical models of the cancer-immune
system interactions. Kuznetsov and Taylor [6] presented a mathematical model
of the cytotoxic T-lymphocyte and responses to the growth of an immunogenic
tumor. They studied the immune-stimulation of tumor growth, ”sneaking
through” of the tumor and the formation of a tumor dormant state. Through
mathematical modeling Kirschner and Panneta [9] have illustrated the dy-
namics between tumor cells, immune effecter cells and interleukin-2 (IL-2).
Their efforts explain both short -term tumor oscillations in tumor size as well
as long-term tumor relapses. Bodnar and U.Fory’s [10] studied the periodic
dynamics in the mathematical model of the immune system. In Murchuk’s
model of immune system dynamics, U.Fory’s [11] presented the model of a
general immune system reaction. The qualitative behavior of the solution to
the model (and its application), along with many illustration of the recov-
ery process, oscillations or lethal outcomes of the disease has been discussed.
In [14], the authors expressed the spontaneous regression and progression of
a malignant tumor system as a prey-predator like system, where the tumor
(cancerous cells) is treated as prey and the cytotoxic T-lymphocytes as preda-
tor. The deterministic model is extended to a stochastic one, allowing random
fluctuations around the positive interior equilibrium. The stochastic stability
properties of the model are investigated both analytically and numerically.
Mallet and De Pillis [15] have presented a hybrid cellular automata partial
differential equation model of moderate complexity to describe the interaction
between tumor and the immune systems of the host. Chaplain et. al. [16] have
explained the effect of time and space in tumor immunology using mathemat-
ical model, that is, the spatio-temporal phenomena. The role of interleukin-2
(IL-2) in tumor dynamics is illustrated through mathematical modeling (a
modified version of the Kirshner-Panetta model) in [17], where the author has
shown that interleukin-2 alone can cause the tumor cell population to regress.
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In [18], the global dynamics of Kirshner-Panetta model is explored and under
what conditions tumor clearance can be achieved, is obtained.
In most of these tumor-immune system interaction models, the immune sys-
tem comprises both antibody mediated and cell mediated immune responses.
In such situations, it is difficult to identify which immune system plays greater
role in the elimination or control of the cancerous cells. In this paper we have
investigated the role of antibodies in the eradication of the cancerous cells
using system of non linear differential equations. The motivation came from
the fact that researchers at the University of Manchester along with their
collaborators at the University of Southampton investigated how antibody
treatments make cancerous cells kill themselves and found a previously undis-
covered mechanism that could, in future, be even more effective in causing
their death. It is known that when antibodies bind to cells, including cancer-
ous cells, they can mark those targets for destruction by the body’s immune
system but Tim Illidge et. al. [1] have shown in their latest study that antibod-
ies can kill cancerous cells directly. When the antibodies binds with cancerous
cells, it causes lysomes (small acid containing sacs) inside the cell to swell and
burst rapidly releasing their toxic contents with fatal results for cancerous
cells, which is non-apoptotic in nature.
Not much work has been done on the role of antibodies to eradicate cancerous
cells through mathematical modeling. This may be due to the fact that no
clinical evidence was available to support the fact that antibodies are actu-
ally capable of killing cancerous cells directly. To the best of our knowledge,
the role of antibodies to eradicate cancer by mathematically modeling the
scenario were done by Dillman and Koziol [19], Kolev [20] and Dubey et. al.
[21]. Dillman and Kziol proposed and developed a pharmacokinetic model for
the quantitative analysis of dose-timecell survival curves devolving from in-
fusions of the murine monoclonal antibody TlOl into patients with chronic
lymphocytic leukemia (CLL) and cutaneous T cell lymphoma (CTCL). Kolev
has described a model of cellular tumor dynamics in competition with the
immune system with the help of integrodifferential equations, where the role
of antibodies has been taken into account. Dubey et. al. have considered many
components of acquired immune response, namely, T Helper cells, Cytotoxic
T-Cells, B-cells which secretes antibodies and their interaction with avascular
cancer cells. They observed that under appropriate conditions this interaction
is capable of controlling the growth of cancerous cells.
In section 2, the whole biological scenario supported by schematic diagram
is explained, followed by mathematical formulation of the model. Estimation
of the system parameters are discussed in section 3 . Linear stability analy-
sis, global stability analysis as well as bifurcation analysis of the system are
explored in section 4. Section 5 deals with the numerical results and their
biological implications. The paper ends with a conclusion.
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2 Model Formulation
The host immune system has the ability to produce some significant anti
cancerous immune responses, one of which is the B-cells. The human body
produces millions of different B-cells each day that circulates in the blood and
lymphatic system performing the role of immune surveillance. The principal
function of B-cells is to secrete antibodies against antigens. Prior to stimu-
lation by either antigen or mitogen, B-cells are morphologically small cells.
The binding of antigen to antigen receptors (i.e. antibodies) on B-cells can
result in the activation and differentiation of small B-cells into large B-cells
which secrete antibodies at a lower rate. A set of immunoglobulin molecules
is present on the surface of unstimulated B-cells [22]. By binding to these im-
munoglobulin receptors and with a possible second signal from an accessory
cell such as the T-cell, the antigen stimulates the B-cell to divide and mature
into terminal (non-dividing) antibody secreting cells called plasma cells. The
plasma cells are most active in secreting antibodies at a much faster rate but
large B-lymphocytes, which proliferate rapidly, also secrete antibody, albeit at
a lower rate. Some of the large B-cells eventually revert back to small B-cells
where they probably function as memory cells, which can respond vigorously
to subsequent antigenic challenges [5]. The secreted antibodies then circulate
in the blood and lymphatic system, and bind to the original antigen, marking
them for elimination by several mechanisms, including activation of the com-
plement system, promotion of phagocytosis via opsonization and mediation
of antibody dependent cell-mediated cytotoxicity (ADDC) with effecter cells
such as macrophage, NK cells and neutrophils.
Based on the above biological scenario and from the clinical evidence that
antibodies can directly kill cancerous cells [1], we present a schematic diagram
(fig.1) to describe the interaction between the cancerous cells, large B-cells,
plasma cells and antibodies. We now propose a mathematical model to de-
scribe the interaction between the host immune system considering the role of
humoral mediated immune responses, that is, the antibodies, and the cancer-
ous cells.
Let L, P, A and T be the number of large B-cells, plasma cells, antibodies and
the cancerous cells respectively at any time t1. It has been observed that the
number of antibody forming cells per spleen increased from the order of 102
to 106 over 96 hours when a single injection of sheep red blood cells is given
to mice [23]. However, when the absolute number of responding cells reaches
the order of 107, density dependent effects may prevent further growth of the
lymphocyte population [24,25]. Therefore, we assume that the large B-cells
grow logistically. The large B-cells can either proliferate with constant intrinsic
growth rate a1 and increase the B-cell population or they can undergo further
differentiation into plasma cells at a constant rate b1. We assume a1 > b1 to
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insure that there can be a net growth in the large B-cells population. Thus,
the governing equation for the large B-cells and the plasma cells are given by
dL
dt1
= a1uL(1−
L
K1
)− b1(1− u)L, (1)
dP
dt1
= b1(1− u)L− µ1P, (2)
where, u (0 < u < 1) is the fraction of the large B-cells which remains as
the proliferating large B-cells and (1 - u) is the fraction that differentiate into
plasma cells, K1 is the carrying capacity of the large B-cell population and µ1
is the natural death rate of the plasma cells.
It is clinically known that both the large B-cells as well as the plasma cells
secrete antibodies, however, plasma cells secrete them at a much faster rate
than the large B-cells. Therefore, the governing equation for the the antibody
is given by
dA
dt1
= r1L+ r2P − µ2A− β1AT, (r1 < r2), (3)
where r1 and r2 are the rate at which the large B-cells and the plasma cells
secrete antibodies respectively, µ2 is the natural death rate of antibodies and
β1 the rate at which the cancerous cells kill the antibodies.
We assume that the cancerous cells grow logistically in the absence of the
antibodies and the antibodies kill the cancerous cells directly [1]. Thus for the
cancerous cells, the governing equation is
dT
dt1
= rT (1−
T
K2
)− β2AT, (4)
where r is the intrinsic growth rate,K2 is the carrying capacity of the cancerous
cells and β2 is the rate at which the antibodies kill the cancerous cells by direct
interaction. The initial conditions for systems (1 − 4) are L(0) = L0, P (0) =
P0, A(0) = A0 and T (0) = T0 respectively.
3 Parameter Estimation
Appropriate parameter values determine the analysis and behavior of a math-
ematical model to describe a given system. Therefore, to complete the de-
velopment of our mathematical model, we estimate the values of the system
6
parameters in the following manner. The mean generation time for large B
lymphocyte is approximated to be 6 to 48 hours [26]. Hence the growth rate
a1 of the large B lymphocyte is estimated to be between 0.02 and 0.2 hr
−1 [5].
Since the immune response to a T-independent antigen generally lacks any de-
tectable immunological memory [27,28], the conversion of large lymphocytes
back into small lymphocytes and the possible subsequent recycling of memory
cells back into large lymphocytes have not been explicitly considered. The life
time of plasma cells ranges from few days to few weeks. Thus the natural
death rate µ2 of the plasma cells is approximated to vary between 0.002 to
0.02 hr−1 [5].
The plasma and large B cells secrete antibodies at different rates. It is known
that the plasma cells may be even 100 fold more active in immunoglobulin
synthesis than the large B cells [29]. Thus, the rate at which the plasma cells
secrete antibodies can be estimated to be 2 to 100 times that of the large B
cells. The secretion rate of antibodies by a single cell also varies considerably.
Different authors estimated the absolute rate of antibody secretion by a single
cell. For example, Nossal and Makela [30] have been found in vitro that the rate
at which a single cell secretes antibodies ranges from 100 to 1500 antibodies
cell−1sec.−1. Conrad and Ingraham [31] found in vivo values that range from
8000 to 20000 antibodies cell−1sec.−1.
The dynamics of cancerous cell (tumors) growth has been studied by numer-
ous authors (V.A. Kuznetsov et. al [6], L.G. Pillis and A. Randunskaya [32],
D. Krischner and J. C. Panetta [9], S. Banerjee and R.R. Sarkar [17]. They
described the dynamics of tumor cell growth using the logistic growth function
as dT/dt = rT (1− T/K2) in the absence of the immune responses, where r is
the intrinsic growth rate and K2 is the carrying capacity. L. G. Pillis et. al.
[33] estimated the parameter values for r and K2 by using the least-squares
distance method and using optimization software with the data in Diefenbach
et. al. [34]. In our case, we use r = 0.431 days−1 and K2 = 9.8 × 10
8 cells
from [33] for the analysis of our model. The interaction terms between anti-
bodies and cancerous cells, namely, β1 and β2 and the natural death rate of
antibodies, that is, µ2 are estimated using synthetic data.
To generate synthetic data, we consider the research article by L.G. de. Pillis
et al. [33]. We first generate a figure (see fig. 2a) taking human data, patient
9, as given in table 2 of [33]. This figure (see fig.2a) reflects the behavior of the
model by De Pillis et. al. [33], who have used parameters taken from exper-
imental results of patient from Rosenberg’s study on metastatic melanoma.
In the generated figure, they have investigated a 106 cells tumor, a tumor
level that in silico innate immune system cannot control on its own. The fig-
ure shows the effect of immunotherapy alone against the tumor, namely, a
TIL (tumor infiltrating lymphocyte) injection, followed by short doses of IL-
2. Using DataThief (www.datathief.org), the data for cancerous cells decay
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are extracted (say, for 20 time points) and some noise is added to the data,
which we name as observed values, Tobs (say). To start the estimation process,
we initially choose (within meaningful biological range) the values of the pa-
rameters to be estimated, namely, β1, β2 and µ2 arbitrarily . Next, we solve
the equations (1 − 4) numerically with these initial values of the parameters
and obtain the solution of the model at those time points, where the observed
values have been obtained, which we name as calculated values, Tcal (say). We
now use least square method to minimize the sum of the residuals, namely,∑20
i=1(T
(i)
cal − T
(i)
obs)
2 to obtain the estimated values of the system parameters,
namely, β1, β2 and µ2. In practise, a MATLAB code has been developed to
carry out the above process and the estimated values of the parameters are
obtained as β1 = 2.5448× 10
−6, β2 = 2.4935× 10
−7 and µ2 = 0.1277. Figure
2b shows the best fit estimate for the model parameters. The corresponding
estimated values of the parameters in non-dimensional form are respectively
α1 = 5786.32, α2 = 566.968 and η2 = 0.2963.
We repeat these processes with five sets of data with different intensity of
noises and succeeded in getting a range of values in which the parameters
β1, β2 and µ2 lies. All the values of the system parameters are given in tabular
form in Table 1.
4 Analysis of the System
To reduce the number of the system parameters and for numerical simulations,
we non-dimensionalize the system using the following scaling,
x=
L
K1
, y =
P
K1
, z =
A
K2
, w =
T
K2
, t = rt1, a =
a1
r
, b =
b1
r
, η1 =
µ1
r
,
η2=
µ2
r
, k1 =
r1K1
rK2
, k2 =
r2K1
rK2
, α1 =
β1K2
r
, α2 =
β2K2
r
.
Then the system can be described as
dx
dt
= aux(1− x)− b(1− u)x, (5)
dy
dt
= b(1 − u)x− η1y, (6)
dz
dt
= k1x+ k2y − η2z − α1zw, (7)
dw
dt
=w(1− w)− α2zw, (8)
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with initial conditions x(0) = x0, y(0) = y0, z(0) = z0 and w(0) = w0. It can
easily be shown that the right hand sides of system (5−8) are continuous and
satisfy Lipschitz condition in R4+.
4.1 Positivity and Boundedness of Solution
Throughout this paper we denote q0 := au − b(1 − u) and assume that it is
positive.
Theorem 1 Let the initial conditions of system (5 − 8) be positive.Then the
solutions (x (t), y (t),z (t), w (t)) of system are non-negative for all t ≥ 0.
Theorem 2 The solutions of system (5− 8) with non negative initial condi-
tions are bounded.
Proof: From equations (5) and (6), we have
d
dt
(x+ y)= aux(1− x)− η1y
=
(η1 + au)
2
4au
− η1(x+ y)− au(x−
η1 + au
2au
)2
≤
(η1 + au)
2
4au
− η1(x+ y).
Hence, using standard differential inequalities, we have x+ y ≤ (η1+au)
2
4auη1
.
Similarly, from equations (7) and (8), since x(t)+ y(t) is bounded (say by k0),
we have
d
dt
(z + w) = k1x+ k2y − η2z + w(1− w)− (α1 + α2)zw
≤ k2(x+ y)− η2(z + w)− (w −
1 + η2
2
)2 +
(1 + η2)
2
4
≤ k2k0 +
(1 + η2)
2
4
− η2(z + w).
Hence (z + w) ≤ k2k0
η2
+ (1+η2)
2
4η2
. Therefore, the solutions of system (5− 8) are
bounded.
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4.2 Equilibria and Local Stability Analysis
The equilibrium points of system (5−8) are E0 = (0, 0, 0, 0), E1 = (0, 0, 0, 1), E2 =
(x¯, y¯, z¯, 0) and E∗ = (x¯, y¯, z∗, w∗), where x¯ = au−b(1−u)
au
, y¯ = b(1−u)x¯
η1
, z¯ = k1x¯+k2y¯
η2
and w∗ = 1−α2z
∗ such that z∗ is the positive roots of the quadratic equation
α1α2z
2 − (α1 + η2)z + (k1x¯+ k2y¯) = 0. (9)
Note: If q0 = au − b(1 − u) < 0 then the cancerous cells free E2 and the
positive interior E∗ equilibrium points of the system will not exist. But, from
the linear stability analysis one can show that the equilibrium point E0 is
unstable and the equilibrium point E1 is stable.
We now study the linear stability of the cancerous cells free and the positive
interior equilibrium points system (5 − 8). The jacobian matrix JE2 at the
boundary equilibrium point E2 is given by
JE2=


−(au− b(1− u)) 0 0 0
b(1− u) −η1 0 0
k1 k2 −η2 −α1z¯
0 0 0 1− α2z¯


and the corresponding characteristic equation is
(λ+ au− b(1− u))(λ+ η1)(λ+ η2)(λ− (1− α2z¯)) = 0. (10)
Therefore, the equilibrium point E2 (the cancerous cells free equilibrium point)
is locally asymptotically stable (LAS) if 1− α2z¯ < 0.
The Jacobian matrix JE∗ at the interior equilibrium point E
∗ is given by
JE∗=


−(au − b(1 − u)) 0 0 0
b(1 − u) −η1 0 0
k1 k2 −η2 − α1w
∗ −α1z
∗
0 0 −α2w
∗ −w∗


Then, the corresponding characteristic equation is
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(λ+ au− b(1− u))(λ+ η1)[λ
2 + (η3 + w
∗(1 + α1))λ+ (11)
w∗(η2 + α1 − 2α1α2z
∗)] = 0
Theorem 3 Let z∗+ and z
∗
−
be roots equation (6). The interior equilibrium
point E∗
−
= (x¯, y¯, z∗
−
, w∗), (the high number of cancerous cells equilibrium
point) is LAS when ever it exists and E∗+ = (x¯, y¯, z
∗
+, w
∗) is unstable.
Proof: From the characteristic equation (11) the equilibrium point E∗ is LAS
provided that the roots of the quadratic equation
λ2 + (η2 + w
∗(1 + α1))λ+ w
∗(η2 + α1 − 2α1α2z
∗) = 0, (12)
are negative or with negative real parts. But from (9) we have,
η2 + α1 − 2α1α2z
∗ = ∓
√
(η2 + α1)2 − 4α1α2(k1x¯+ k2y¯)
Hence, the roots of equation (11) are negative or with negative real parts
if η2 + α1 − 2α1α2z
∗ > 0. Therefore, E∗
−
= (x¯, y¯, z∗
−
, w∗) is LAS and E∗+ =
(x¯, y¯, z∗+, w
∗) is unstable.
4.3 Global Stability Analysis
We now study the global stability of E2, the cancerous cells free equilibrium
point and E∗
−
, the high number of cancerous cells equilibrium point.
Theorem 4 The cancerous cells free equilibrium point E2 is globally asymp-
totically stable if α2 >
(α1+η2)2
4α1(k1x¯+k2y¯)
.
Proof: One can easily show that
η2
k1x¯+ k2y¯
<
(α1 + η2)
2
4α1(k1x¯+ k2y¯)
.
Then, α2 >
(α1+η2)2
4α1(k1x¯+k2y¯)
implies that 1 − α2z¯ < 0. Hence the cancerous cells
free equilibrium point E2 is LAS. From equation (5) we have
x(t) =
q0
au(1− ce−q0t)
,where c = 1−
q0
aux0
.
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Hence, limt→∞ x(t) =
au−b(1−u)
au
= x¯. From the definition of limit superior, for
any ǫ > 0, we have
dy
dt
= b(1− u)x− η1y ≤ b(1 − u)(x¯− ǫ)− η1y.
Hence,
lim sup
t→∞
y(t) ≤
b(1− u)x¯
η1
= y¯, (since ǫ is arbitrarily small).
Similarly using the definition of limit inferior one can show that
lim inf
t→∞
y(t) ≥
b(1− u)x¯
η1
= y¯.
Therefore, limt→∞ y(t) =
b(1−u)x¯
η1
= y¯. On the other hand, from equation (7)
and using the definition of limit superior, for ǫ > 0, we have
dz
dt
= k1x+ k2y − η2z − α1zw,
≤ k1x+ k2y − η2z,
≤ η2(
k1x¯+ k2y¯
η2
− z).
Therefore, lim sup
t→∞
z(t)≤
k1x¯+ k2y¯
η2
= z¯.
Thus, for every ǫ > 0, there exist a time T1 such that z(t) ≥ (z¯− ǫ) for t ≥ T1.
Using this inequality in the equation (8) we have,
dw
dt
= w(1− α2z − w) ≤ w(1− α2(z¯ − ǫ)− w)
Since ǫ is arbitrarily small and w(t) is non negative for all t > 0, we have,
lim supt→∞w(t) = 0. Therefore, for α2 >
(α1+η2)2
4α1(k1x¯+k2y¯)
, the cancerous cell free
equilibrium point E2 = (x¯, y¯, z¯, 0) is globally asymptotically stable.
Theorem 5 The positive interior equilibrium point E∗
−
is globally asymptot-
ically stable if (1− α2z¯) > 0.
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Proof: For 0 < α2 <
1
z¯
, the equilibrium point E∗
−
is LAS. From theorem (4),
we have limt→∞ x(t) = x¯, limt→∞ y(t) = y¯ and
dw
dt
≤ w(1 − α2(z¯ − ǫ) − w).
Then, lim supt→∞w(t) ≤ (1−α2(z¯−ǫ)), if (1−α2(z¯−ǫ)) > 0. But since ǫ > 0
is arbitrarily small, we have lim supt→∞ w(t) ≤ (1 − α2z¯) =: w
∗
0, provided
that (1 − α2z¯) > 0. From the definition of limit superior, for every ǫ > 0,
w(t) ≤ (w∗0 + ǫ) for all t > 0. Substituting this in equation (7) we get
dz
dt
≥ k1x¯+ k2y¯ − (η2 + α1(w
∗
0 + ǫ))z
= (η2 + α1(w
∗
0 + ǫ))(
k1x¯+ k2y¯
η2 + α1(w∗0 + ǫ)
− z).
Then, using differential inequality we have
lim inf
t→∞
z(t) ≥
k1x¯+ k2y¯
η2 + α1(w∗0 + ǫ)
.
Since, ǫ > 0 is arbitrarily small, we have
lim inf
t→∞
z(t) ≥
k1x¯+ k2y¯
η2 + α1w
∗
0
=: z∗0 .
From the definition of limit inferior, for every ǫ > 0, there exist a time T2 such
that z ≤ z∗0 + ǫ for all t ≥ T2. Substituting this inequality in equation of (8)
once again we get the inequality dw
dt
≥ w(1 − α2(z
∗
0 + ǫ) − w), which intern
implies that
lim inf
t→∞
w(t) ≥ 1− α2z
∗
0 =: w
∗
as ǫ > 0 is arbitrarily small. From the definition of limit inferior, for every
ǫ > 0, w ≥ w∗ − ǫ for all t > 0. Therefore,
dz
zt
≤ (η2 + α1(w
∗ − ǫ))(
k1x¯+ k2y¯
η2 + α1(w∗ − ǫ)
− z)
and hence
lim sup
t→∞
z(t) ≤
k1x¯+ k2y¯
η2 + α1w∗
=: z∗,
since again as ǫ > 0 is so small. From the definition of limit superior again, for
every ǫ > 0, we have z ≥ z∗ − ǫ for all t > 0. Substituting this inequality in
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equation (8), we get dw
dt
≤ w(1−α2(z
∗− ǫ)−w) and hence lim supt→∞w(t) ≤
1− α2z
∗ =: w∗, as ǫ is arbitrarily small. Now
lim sup
t→∞
z(t)− lim inf
t→∞
z(t) = z∗ − z∗0
=
k1x¯+ k2y¯
η2 + α1w∗
−
k1x¯+ k2y¯
η2 + α1w
∗
0
=
α1(k1x¯+ k2y¯)
(η2 + α1w∗)(η2 + α1w∗0)
(w∗0 − w
∗)
=
α2α1(k1x¯+ k2y¯)
(η2 + α1w
∗
0)(η2 + α1w
∗)
(z∗0 − z0)
=
α2α
2
1(k1x¯+ k2y¯)
2
η2(η2 + α1w∗0)
2(η2 + α1w∗)
(−w∗0) < 0,
which is a contradiction since w∗0 = 1− α2z¯ > 0. Therefore,
lim supt→∞ z(t) = lim inf t→∞ z(t) = z
∗. Similarly,
lim supt→∞w(t)− lim inf t→∞w(t) = w
∗
0−w
∗ = α2(z
∗
0−z
∗) < 0, which is again
a contradiction. Therefore,
lim
t→∞
(x(t), y(t), z(t), w(t)) = (x¯, y¯, z∗
−
, w∗),
and hence the positive interior equilibrium point E∗
−
= (x¯, y¯, z∗
−
, w∗) is globally
asymptotically stable.
4.4 Bifurcation Analysis
In this section, we explore the critical parameter values where the qualita-
tive behavior of the system changes. By using the Dulac-Bendixson theorem,
one can show that system (5 − 8) has no closed orbit for positive solutions.
Equations (5) and (6) can be evaluated analytically as,
x(t) =
q0
au(1− ce−q0t)
,where c = 1−
q0
aux0
y(t)= y0e
−η1t + b(1− u)
∫ t
0
eη1(s−t)x(s)ds,
which are not closed orbits. To show that the other solutions are also not a
closed orbit, we consider the function m(w, z) = 1
wz
. Then
14
L=
∂
∂z
(m(w, z)
dz
dt
) +
∂
∂w
(m(w, z)
dw
dt
)
=
∂
∂z
(
1
wz
(k1x+ k2y − η2z − α1zw)) +
∂
∂w
(
1
wz
(w(1− w)− α2zw))
=−
1
z
(
k1x+ k2y
wz
+ 1).
Since all the parameter values are positive, L < 0 over the domain of interest
and hence the system satisfies the Dulac-Bendixson theorem. Therefore, there
are no limit cycles or homoclinic connections for the system. Similarly, from
the values of the eigenvalues of the corresponding Jacobian matrix, there are
no Hopf bifurcations, which may give rise to the occurrence of limit cycles.
The system has different steady states depending on the values of the system
parameters. The equilibrium points E0 = (0, 0, 0, 0) and E1 = (0, 0, 0, 1) exist
for all parameter values. The cancerous cells free steady state E2 = (x¯, y¯, z¯, 0)
exists if au−b(1−u) > 0. The other two positive steady states E∗ exist under
the following conditions:
(i) Let α1 − η2 > 0. The equilibrium point E
∗
+ exist if
1
z¯
< α2 <
(α1+η2)2
4α1(k1x¯+k2y¯)
,
and the equilibrium point E∗
−
exist if α2 <
(α1+η2)2
4α1(k1x¯+k2y¯)
.
(ii) Let α1 − η2 < 0. The equilibrium point E
∗
−
exists if α2 <
1
z¯
.
All these situations are sketched in fig.3.
The stability of the cancerous cells free equilibrium point E2 changes as the
value of the parameter α2 passes through the critical value α21 =
1
z¯
= η2
(k1x¯+k2y¯)
.
Hence α2, which represents the effectiveness of the antibodies to destroy the
cancerous cells, is the bifurcation parameter for the system. The Jacobian
matrix J at E2 and its transpose have a simple eigenvalue λ = 0 with cor-
responding eigenvector vT = (0, 0,−α1z¯
η2
, 1) and wT = (0, 0, 0, 1) respectively
at the bifurcation parameter value α2 =
1
z¯
. If fα2 denote the vector of partial
derivatives of the components of the right hand side of system (5 − 8) with
respect to the scalar α2 and Df(E2, α2)v is the directional derivative of f in
the direction of v at the equilibrium point E2, then,
wT fα2(E2) = 0,w
T [Dfα2(E2, α21)v] =−
z¯
||v||
= −
1
α2||v||
, and
wT [D2f(E0, α21)(v,v)] =
2(α1 − η2)
η2||v||2
,
which are non-zero for α1 − η2 6= 0. Therefore, by Sotomayor theorem [35],
the system experiences transcritical bifurcation at the cancerous cells free
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equilibrium point E2 = (x¯, y¯, z¯, 0), as the parameter α2 passes through the
bifurcation parameter value α2 = α21 =
1
z¯
.
Again, as the value of α2 passes through the critical value α2 = α22 =
(α1+η22)
4α1(k1x¯+k2y¯)
, the number of positive interior equilibrium points of the system
changes. As the value of α2 passes through the critical value α22, the pos-
itive interior equilibrium points E∗+ and E
∗
−
collide and disappear. At the
critical value of α2 = α22 the system has new interior equilibrium point E∗ =
(x¯, y¯, α1+η2
2α1α2
, α1−η2
2α1
), provided α1−η2 > 0. Then the Jacobian matrix J at E∗ and
its transpose has a simple eigenvalue λ = 0 with corresponding eigenvectors
vT = (0, 0,− 1
α2
, 1) and wT = (−α2(b(1−u)k2+η1k1)(α1−η2)
α1η1q0(α1+η2)
,−α2k2(α1−η2)
α1η1(α1+η2)
, α2(
1
α1
−
2
α1+η2
), 1) respectively, corresponding to the eigenvalue λ = 0 at the critical
value α2 = α22. Then,
wT fα2(E∗, α22)=−
(α1 + η2)(α1 − η2)
4α2α21
, and
wT [D2(f(E∗, α22)(v,v))] =
4η2
(α1 + η2)||v||2
,
which are non-zero for α1 6= η2. Therefore, by Sotomayor theorem, there is a
smooth curve of the equilibrium point of the system in R4×R passing through
the point (E∗, α22) and tangent to the hyper plane R
4
+×α22. Hence, the system
has a saddle-node bifurcation as the parameter α2 passes through the critical
bifurcation parameter value α2 = α22.
5 Numerical Results and Biological Implications
In this section we present the numerical results of system (5 − 8) for the
parameter values given in Table 1. The steady sate E0 = (0, 0, 0, 0) and
E1 = (0, 0, 0, 1) exist for the parameter values given in Table 1. The cancerous
cells free equilibrium point E2 = (x¯, y¯, z¯, 0) exists for the system parameters
provided that au > b(1− u), which holds true for the parameter values given
in Table 1. If α21 = 0.227538 < α2 < α22 = 1111.032892, the positive interior
equilibrium points E∗+, characterized by relatively low number of cancerous
cells and E∗
−
, characterized by relatively high number of cancerous cells exist
keeping the other parameter values fixed. For 0 < α2 < α21 = 0.227538, only
the high number of cancerous cells equilibrium point E∗
−
exists. As the value
of α2 increases and passes through the critical value α22 = 1111.032892, the
equilibrium points E∗+ and E
∗
−
collide and disappear.
By linearizing the system about the steady states, the stability of the equi-
librium points are determined, which is important from physiological point
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of view. From the linear stability analysis we have seen that, the equilibrium
points E0 = (0, 0, 0, 0) and E1 = (0, 0, 0, 1) are unstable for au− b(1− u) > 0
and the cancerous cells free equilibrium point E2 is stable if 1−α2z¯ < 0, that
is, α2 >
1
z¯
= 0.227538 and unstable otherwise. The stability of E2 implies that
the antibodies can clear the cancerous cells. As α2 passes through the criti-
cal value α21 = 0.227538, the stability of E2 changes from unstable to stable
and hence the system has a transcritical bifurcation at this point. Using the
software Matcont, the point at which the system experiences transcritical
bifurcation is BP = ( 0.550000 0.495000 4.394869 0.000000 0.227538 ), where
x = 0.55, y = 0.495, z = 4.394869, w = 0.00 and α2 = α21 = 0.227538. As
the value of α2 passes through the critical value α22 = 1111.032892 the two
positive interior equilibrium points collide and disappear, where the system
experiences a saddle node bifurcation at this point. Using Matcont, the point
at which the system experiences the saddle node bifurcation is given by LP =
( 0.550000 0.495000 0.000450 0.499974 1111.032892 ), where x=0.55, y=0.495,
z=0.000450, w=0.499974 and α2 = α22 = 1111.032892. This is shown in fig.4a
and 4b, where BP is the branching point, LP is the limit point and H is the
neutral saddle, which has no meaning in the biological context. Also, it has
been shown that E2 attains global stability provided that α2 > α22.
The high number of cancerous cells equilibrium point E∗
−
is stable whenever it
exists and E∗+ is unstable always. In the region 0 < α2 < α21, the high number
of cancerous cells equilibrium point is the only stable (globally stable) equilib-
rium point of the system and hence the cancerous cells succeed to survive. This
is depicted in fig.5, which implies that the cancerous cells will escape immune
surveillance unless each and every cancerous cells are killed, that is, the system
will ineluctably return to the high-cancer state if the treatment is stopped.
Thus, in order to realistically effect a cure when the cancer free equilibrium
point is unstable, a therapy or treatment must ensure that not only the can-
cer burden must be reduced but the therapy itself is capable of changing the
parameter values of the system. In this context, monoclonal antibody therapy
of cancer [36] is suggested as treatment, which may be capable of changing
the system parameters. Monoclonal antibodies (MAbs) can be used to target a
number of cancer associated targets, including tumor associated blood vessels,
vascular growth factors, diffuse malignant cells like leukemia, cancerous cells
with a solid tumor and tumor associated stroma like fibroblasts.
If α21 < α2 < α22, then both the cancerous cells free equilibrium E2 and the
high number of cancerous cells equilibrium E∗
−
are stable, that is, this region
is the region of bistability. In this region, the system is sensitive to the initial
conditions and some parameter values. Depending on the initial conditions
and some of the values of the system parameters given in Table 1, a given
initial value of the cancerous cell will either grow to the stable high number of
cancerous cells equilibrium point E∗
−
(the cancerous cells succeed to survive)
or decays to the cancerous cells free equilibrium point E2 (the immune system
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succeeds in eradicating the cancerous cells). Fig.6 captures the dynamics of the
sensitivity of the system with respect to the initial conditions. The sensitivity
of the system on the parameter α2 is shown in fig.7.
As the value of α2 increases towards the critical value α22, the quantity of the
high number of cancerous cells equilibrium point decreases to about half the
carrying capacity K2 of the cancerous cells. When the value of α2 increases
and exceeds the critical value α22, any amount of cancerous cells decays to
zero after some time, that is, the immune system succeed in clearing the
cancerous cells. The time at which a given amount of cancerous cells drops to
zero depends on the initial conditions and some values of system parameters.
When α2 > α22, there is only cancer free equilibrium and it is stable. Fig.8
shows, once the critical point α22 is crossed, the cancerous cells always decays
to zero, no matter what the initial values are.
As stated earlier, the effect of monoclonal therapy, which is capable of changing
the system parameter, is evidently visible in this region, that is, when α2 > α22.
In this therapy, a monoclonal antibody can be directed to attach to certain
cancerous cells. Cetuximab (Erbitux), a monoclonal antibody approved to
treat colon cancer and head and neck cancers, attaches to receptors on cancer
cells that accept a certain growth signal (epidermal growth factor). Cancer
cells and some healthy cells rely on this signal to tell them to divide and
multiply. Blocking this signal from reaching its target on the cancerous cells
may slow or stop the cancer from growing. There are a number of monoclonal
antibody drugs that are available to treat various types of cancer by (a) making
the cancerous cells more visible to the immune system (b) delivering radiation
to cancerous cells (c) slipping powerful drugs into cancerous cells. Recent
clinical investigations show that they are capable of killing cancerous cells
directly [1]. However, more clinical trials are necessary before it comes out in
the form of medicine to mimic that effect.
6 Conclusion
In this paper, we have formulated a system of non-linear ordinary differential
equations that describes the stimulatory effect of cancerous cells on immune
cells in conjunction with antibodies. The model we have proposed is simple
and more of general type. The major difference of our model from that of the
existing literature in this direction is that the immune system we considered
here is antibody mediated T-cell independent immune responses. In this dy-
namics, a significant role is played by α2, the effectiveness of the antibodies
to kill the cancerous cells directly.
From our study we observe that for certain values of α2, one can control the
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unlimited growth of the cancerous cells. From the analysis of our model, we
determine some criterion for the existence of the equilibrium points of the
system and the stability conditions. For a specific set of parameter values,
we obtain five equilibrium points, namely,the zero equilibrium point E0, the
boundary equilibrium point E1, the cancer-free equilibrium point E2 and two
positive interior equilibrium points E∗. Initially, the cancerous cells free equi-
librium point was unstable and the high number of cancerous cell equilibrium
point was stable (α2 < α21). This means any treatment to be effective, it
must have the ability to change the system parameter and force this desirable
equilibrium point to become stable.
On the other hand, the stability of the high number of cancerous cells equi-
librium point implies that reducing the cancer burden through any effective
treatment is not sufficient enough to kill all the cancerous cells. Once the treat-
ment stops, the system, even with an untraceable sign of cancer, will return
to high number of cancerous cells state. However, alteration of system param-
eters through monoclonal antibody therapy of cancer, may have the ability to
change the stability nature of the cancer free equilibrium point and allowing
a new treatment protocol to eradicate cancerous cells. In fact, it has been
tested clinically that monoclonal antibodies directed to CD20 and HLA-DR
can elicit homotypic adhesion followed by lysosome-mediated cell death in hu-
man lymphoma and leukemia cells [36]. In the stability analysis of our model,
we obtain a region of bi-stability and observe that the growth of the cancerous
cells can be controlled and reduced at early stage of its growth by enhancing
the patient’s own defense mechanism, that is, the antibodies to fight against
the cancerous cells.
We perform bifurcation analysis of the system for the parameter α2, which
represents the effectiveness of antibodies to eliminate cancerous cells. From
the analysis, we observed that for certain parameter values of the system, the
long term behavior of the system can be sensitive to the initial number of the
cancerous cells. In the region where there is bi-stability (the stability region of
both the cancer free and high number of cancerous cells equilibrium points),
for the cancerous cell population that are very close to the boundary separat-
ing the region of attraction of these equilibrium points, a slight change in the
initial conditions will change the behavior of the system. One important impli-
cation of this result for the treatment of cancer is that if both the cancer-free
and high number of cancerous cells equilibria are stable, then for cancerous
cell population that are close to the boundary separating the basins of attrac-
tion of these equilibria, very small changes in the initial number of cancerous
cells can have drastic consequences on the outcome of the cure. Therefore, by
determining some of the values of the system parameters, we can achieve the
stable cancerous cells free equilibrium point to cure the disease. At the end
we would like to mention that the model can be modified further by adding
delay terms, diffusive terms and stochastic fluctuations to the system to bring
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out more rich dynamics of the system, which we propose as our future work.
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Table 1
Parameter values used for numerical illustration
Parameters Values Scaled References
a1(the growth rate of large B-cells) (0.02− 0.2) hr.
−1 0.0464 -0.464 [5]
b1(the conversion rate of large b-cells
into plasma cells)
0.01 hr.−1 0.0232 [5]
µ1(the natural death rate of plasma
cells)
(0.002− 0.02) hr.−1 0.00464-0.0464 [5]
K1(the carrying capacity of large B-
cells)
106cells − [5]
u (the fraction of daughter cells which
remain as large B-cells)
0.1 − [5]
r1(the rate at which large B-cells se-
crete antibodies)
100 Ab cell−1 sec.−1 0.236754 [29,30,31]
r2(the rate at which plasma cells se-
crete antibodies)
1000 Ab cell−1 sec.−1 2.36754 [29,30,31]
µ2(the natural death rate of antibodies) 0.1277− 0.6465 sec.
−1 0.2963 - 1.5 estimated
β1(the death rate of antibodies due to
interaction with cancerous cells)
6.0436 × 10−9 − 2.5448 ×
10−6 cell−1hr.−1
13.7418 -5786.32 estimated
r (the intrinsic growth rate of cancerous
cells)
0.431 day−1 − [33]
K2(the carrying capacity of cancerous
cells)
9.8× 108 cells − [33]
β2(the death rate of cancerous cells due
to interaction with antibodies)
9.0135× 10−10 − 2.4935×
10−7 Ab−1 hr.−1
2.05− 566.968 estimated
23
Fig. 1. The schematic diagram illustrates the interaction between large B-cells,
plasma cells, antibodies and the cancerous cells
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Fig. 2. The figure shows how syntectic data generated and used to estimate the
parameters β1, β2 and µ2. Fig. 2a is generated by taking the model and human data,
patient 9 as given in table 2 of [33]. Fig. 2b shows the best fit estimate for the model
parameters β1, β2 and µ2.
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Fig. 3. The figure shows the existence and stability regions of the equilibrium points
E2, E
∗
+ and E
∗
−
, where k = k1x¯+k2y¯. R1 (α1−η2 < 0 and 0 < α2 < α21 = 0.227538)
is the region where E2 and E
∗
−
exist such that E2 is unstable and E
∗
−
is sta-
ble. R2 (α1 − η2 > 0 and 0 < α2 < α21 = 0.227538), is the region where
both E2 and E
∗
−
exist and stable (bistability region). R3 (α1 − η2 > 0 and
α21 = 0.227538 < α2 < α22 = 1111.032892) is the region where the equilibrium
points E2, E
∗
−
and E∗+ exist and both E2 and E− are stable ( bistability region) and
E∗+ is unstable. In the region R4 (α2 > α22) the equilibrium point E2 exists and it
is stable.
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Fig. 4. The figure shows the points of bifurcation for the system parameter α2, which
has been obtained using the software Matcont. Here, H represents neutral saddle, BP
is the branching point and LP is the limiting point. The branching point occurs at
α2 = 0.227538, which is identified as the transcritical bifurcation point and the limit
point occurs at α2 = 1111.032892 which is identified as the saddle node bifurcation
of the system. Other system parameter values are fixed, which is given in Table 1.
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Fig. 5. The figure shows that in the region 0 < α2 < α21 = 0.227538, the unique
positive interior equilibrium point E∗
−
characterized by high number of cancerous
cells (nearly equal to the carrying capacity K2) is stable. Setting α2 = 0.04 with any
initial conditions (a) IC = (0.5,0.49,4.39,0.01) and (b)IC = (0.5,0.49,0.004,0.5),
the cancerous cells grow to the high number of cancerous cells equilibrium point E∗
−
.
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Fig. 6. The figure shows how the system is sensitive to the initial conditions in the
region of bistability, that is, α21 < α2 < α22 . Setting α2 = 800, (a) initial conditions
IC = (0.5,0.49,0.0004,0.3) shows that the cancerous cells grow to the high number
of cancerous cells equilibrium point E∗
−
. (b) However, a fraction of cell difference
in the number of cancerous cells IC = (0.5,0.49,0.0004,0.2) shows that it decays to
zero, to the cancerous free equilibrium point E2.
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Fig. 7. The figure illustrates that with the same initial condition IC =
(0.5,0.49,0.0004,0.2) and for different values of α2, the system has different be-
havior. (a) For α2 = 726, the cancerous cells grow to the high number of cancerous
cells equilibrium point and (b) for α2 = 727, it decay to the cancerous cells free
equilibrium point.
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Fig. 8. The figure shows when the value of α2 = 1200 greater than the criti-
cal value α22 = 1111.03 for different values of the initial conditions (a) IC =
(0.5,0.49,0.0004,0.4)and (b) IC = (0.5,0.49,0.0004,0.85), the cancerous cells always
decay to zero.
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